Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. (NASDAQ: OCGN) regularly issues news updates about its progress in gene therapies for blindness diseases, making its news flow particularly relevant for investors and observers of the ophthalmic biotechnology space. The company’s announcements often cover clinical trial milestones, licensing agreements, financing transactions, and participation in industry and investor conferences.
A major focus of Ocugen’s recent news has been its modifier gene therapy platform and associated programs. Updates include Phase 1, Phase 2, and Phase 2/3 data for investigational products such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease. Press releases describe safety and exploratory efficacy findings, such as lesion growth reduction and visual function outcomes, as well as plans for future regulatory submissions.
Ocugen’s news stream also highlights business development and capital markets activity. Examples include an exclusive license agreement with Kwangdong Pharmaceutical Co., Ltd. for OCU400 in the Republic of Korea, registered direct offerings of common stock and warrants, and updates on cash runway and financial results. In addition, the company frequently announces webcasts and conference calls to discuss quarterly results, business updates, and key clinical data readouts.
Another recurring theme in Ocugen’s news is its presence at healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference, NobleCon, and rare disease–focused events. These items outline presentation topics, panel participation, and the company’s messaging around its goal of advancing multiple Biologics License Application (BLA) filings within a defined timeframe.
Investors and followers of OCGN news can use this page to monitor clinical trial progress, licensing developments, financing events, and strategic communications as Ocugen advances its gene therapy programs for major retinal diseases.
Ocugen (NASDAQ: OCGN) has announced the dosing of its first patient in the Phase 2/3 GARDian3 pivotal confirmatory trial for OCU410ST, a modifier gene therapy candidate for Stargardt disease. The trial follows encouraging Phase 1 results that showed 48% slower lesion growth and a statistically significant 2-line gain in visual acuity at 12-month follow-up.
The Phase 2/3 study will enroll 51 participants, with 34 receiving a one-time subretinal injection of OCU410ST and 17 serving as untreated controls. The therapy targets ABCA4-associated retinopathies, affecting approximately 100,000 patients in the U.S. and Europe. Ocugen plans to submit a Biologics License Application (BLA) in 2027, based on one-year follow-up data.
Ocugen (NASDAQ: OCGN), a biotechnology company focused on gene therapies for blindness diseases, has scheduled its Q2 2025 earnings conference call for August 1, 2025, at 8:30 a.m. ET. The company will release its financial results before the market opens on the same day.
Investors can access the call via U.S. dial-in (800-715-9871) or international dial-in (646-307-1963) using conference ID 9627149. A webcast will be available on Ocugen's investor relations website, with a replay accessible for approximately 45 days after the event.
Ocugen (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for blindness diseases, has scheduled a conference call and live webcast for Friday, May 9, 2025, at 8:30 a.m. ET. The event will cover the company's first quarter 2025 financial results and provide business updates.
The company will release its earnings announcement before the market opens on May 9. Investors can join via phone using U.S. dial-in (800) 715-9871 or international dial-in (646) 307-1963 with Conference ID 1773288. A webcast will be available on Ocugen's investor site, with a replay accessible for approximately 45 days after the event.
Ocugen announced upcoming presentations of its modifier gene therapy platform at two major ophthalmology events: The ARVO 2025 Annual Meeting in Salt Lake City (May 4-8) and Retina World Congress in Ft. Lauderdale (May 8-11). The company will showcase three key therapies:
- OCU400 for retinitis pigmentosa (Phase 3 LiMeliGhT trial)
- OCU410ST for Stargardt disease (Phase 2/3 pivotal trial)
- OCU410 for geographic atrophy (Phase 2 ArMaDa trial)
CEO Dr. Shankar Musunuri confirmed plans to file three Biologics License Applications/Marketing Authorization Applications within three years. The presentations include clinical trial updates, safety data, and efficacy results across multiple sessions. Dr. Huma Qamar, Chief Medical Officer, will lead the company showcase at Eyecelerator and participate in panel discussions at both events.